...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells
【24h】

A review of the role of surgery for small cell lung cancer and the potential prognostic value of enumeration of circulating tumor cells

机译:小细胞肺癌手术的作用及循环肿瘤细胞计数的潜在预后价值综述

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Small cell lung cancer (SCLC) is disseminated in the majority of patients at first presentation and, thus, treated with chemoradiotherapy. Despite initial high response rates, chemoresistance appears rapidly and results hi a dismal prognosis. However, patients with limited cancer may exhibit better disease control upon surgical treatment. Correct staging is highly critical in the selection of those patients which are likely to benefit from surgery. Studies of the inclusion of surgery in the multimodal treatment of SCLC vary widely in number of patients, selection, treatment and follow-up. Nevertheless surgical therapy for confined SCLCs achieves favorable long-term survival compared to chemoradiotherapy, depending on a precise assessment of the degree of tumor dissemination. Recently, extremely high counts of circulating tumor cells (CTCs) were reported in patients with SCLC compared to other malignancies. In several studies the number of CTCs was found to constitute a prognostic parameter and a marker of response to therapy. Therefore, the assessment of CTCs as so-called "Liquid Biopsy" seems to constitute a more precise method to detect tumor dissemination earlier when compared to clinical staging. In conclusion, in the era of precision oncology enumeration and identification of CTCs of SCLC patients have the potential to help in the selection of patients most suitable for tumor surgery. (C) 2016 Elsevier Ltd, BASO similar to the Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
机译:小细胞肺癌(SCLC)在初次就诊时在大多数患者中传播,因此接受放化疗。尽管最初的反应率很高,但化学耐药性迅速出现,结果预后不良。但是,癌症有限的患者可能在手术治疗后表现出更好的疾病控制能力。在选择可能受益于手术的患者时,正确的分期至关重要。在SCLC的多模式治疗中纳入外科手术的研究在患者数量,选择,治疗和随访方面差异很大。然而,取决于放疗程度的精确评估,与放化疗相比,局限性小细胞肺癌的手术治疗可实现良好的长期生存。最近,与其他恶性肿瘤相比,SCLC患者的循环肿瘤细胞(CTC)数量极高。在几项研究中,发现四氯化碳的数量构成了预后参数和对治疗反应的标志。因此,与临床分期相比,将CTC评估为所谓的“液体活检”似乎是一种更精确的方法,可以更早地检测出肿瘤的扩散。总之,在精确肿瘤学时代,SCLC患者的CTC枚举和鉴定有可能帮助选择最适合肿瘤手术的患者。 (C)2016 Elsevier Ltd,类似于癌症手术协会的BASO和欧洲外科肿瘤学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号